Walking has been studied in 983 papers since 1983: 256 trials and 573 observational studies in people, 4 in animals, 114 reviews; 283 in the past year. The newest story, Nov 11, 2026: “Walking linked to better thinking scores in older adults”.
Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
Walking improves cognitive function in humans (compared with control without structured walking intervention) (slope estimate = 0.39).
“the wearable-assisted walking intervention was associated with a significantly steeper increase in cognitive function (slope estimate = 0.39, p < .001)”
Human trialcompared with control without structured walking interventionwearable-assisted12 weeksn = 120
Walking improves cognitive function in humans (Pre- to post-condition comparison).
“inhibitory control, working memory, task shifting, processing speed and the fluid composite score (P < .01 for all) improved from pre-to post-condition for all conditions.”
Human trialPre- to post-condition comparisonModerate intensity20 minutesn = 29
American journal of Alzheimer's disease and other dementias·
All 25Fewer
Gait speed
↑upin humans6↔no changein humans3
9 studies
Walking improves gait speed in humans (-0.74 s, 95% CI -1.13 to -0.36).
“and a 0.74 s lower 5YWT time (95% CI −1.13 to −0.36; p < 0.001; q = 0.001) versus the control; both remained significant after correction across eight outcomes”
Walking improves gait speed in humans (uncontrolled trial) (improved by 0.096 ±0.017 meter/second).
“As shown in Table, from baseline to follow-up we observed a significant increase in the number of steps taken per day and significant improvements in gait speed (improved by 0.096 ±0.017 meter/second), TUG (improved by 0.8 second), and BMI (improved by 0.3 kg/m2).”
Walking improves gait speed in humans (Older Veterans; baseline-to-follow-up comparison without a control group) (1.13 ±0.20 to 1.24 ± 0.23 meter/second).
“Improvement in gait speed (1.13 ±0.20 vs. 1.24 ± 0.23 meter/second, p<0.0001)”
Human trialOlder Veterans; baseline-to-follow-up comparison without a control groupstructured, low-intensity walking program6 weeks88% malesn = 185
“Meta-analyses showed positive effects of voluntary walking on gait speed (ie, short walking tests, standardized mean difference [SMD]=0.59 [0.26-0.93])”
International journal of environmental research and public health·
Walking improves physical function in humans.
“Except for participant I01, and cadence data on participant I02, the walking speed, step length, and cadence increased across all other participants in the intervention group.”
“Among the primary outcomes, participants in both intervention groups showed significant within-subject differences in the Physical Function subscale of the health-related quality of life scale only, with F(1,20) = 23.03, p < 0.001, and F(1,18) = 27.22, p < 0.001, respectively.”
European journal of investigation in health, psychology and education·
Walking improves physical function in humans (older adults with mild to moderate cognitive impairment in assisted living).
“Significant effects favoring the intervention were shown for all outcomes.”
Human trialolder adults with mild to moderate cognitive impairment in assisted livingwatch-prompted light walking10 min three times a day10 weeksn = 25
Walking decreases blood pressure in humans (Peripheral artery disease and claudication) (Systolic BP: -6.7 ± 8.9 mm Hg; diastolic BP: -1.2 ± 4.1 mm Hg).
“both walking and AC induced post-exercise hypotension in patients with PAD”
Human trialPeripheral artery disease and claudication15 bouts of 2 minutes; intensity 4 to 6 on a modified (1-10) Borg Rating of Perceived Exertion scaleAcute53% mensn = 17
Journal of cardiopulmonary rehabilitation and prevention·
Walking decreases blood pressure in humans (−7.0 mm Hg, 95% CI −3.9 to −10.0 mm Hg).
“Systolic blood pressure decreased from 137 ± 10 mm Hg at baseline to 132 ± 13 mm Hg (p = 0.008, gav = 0.41; mean difference from baseline (95% confidence interval [CI]): −4.2 (−1.1, −7.2) mm Hg) at 10 weeks and to 130 ± 11 mm Hg (p < 0.001, gav = 0.64; mean difference from baseline (95% CI): −7.0 (−3.9, −10.0) mm Hg) at 20 weeks (overall p < 0.001”
Journal of cardiovascular development and disease·
Walking showed no clear effect on blood pressure in humans.
“No differences were observed between groups for mean change in heart rate (p = 0.06), systolic blood pressure (p = 0.49), diastolic blood pressure (p = 0.60), or body mass index (p = 0.65).”
Walking showed no clear effect on frailty in humans (RR 0.81, 95% CI 0.61–1.06).
“Adjusted week-12 comparisons remained inconclusive: walking RR 0.81 (95% CI 0.61–1.06; p = 0.118), resistance training RR 0.87 (95% CI 0.63–1.20; p = 0.389), and Traditional Chinese exercise RR 0.93 (95% CI 0.67–1.29; p = 0.665).”
European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity·
Walking is linked with frailty in humans (mediating built environment and frailty onset).
“We found that walking time, depression, and social support were mediating factors in the relationship between built environment and the onset of frailty.”
Humansmediating built environment and frailty onset3 yearsn = 38,829
Walking decreases systolic blood pressure in humans (moderate-intensity walking interruptions (6.0 km/h) compared to uninterrupted sitting) (~ 6 mmHg).
“Compared to the CC, SBP was ~ 6 mmHg lower in MIPA after 3 hours (CG: 114 ± 13.9 mmHg vs. MIPA: 108 ± 10.6 mmHg; p = 0.005; 95% CI: 2.03 to 11.01; Hedges’ g = 0.48) (Fig. 4a).”
Human trialmoderate-intensity walking interruptions (6.0 km/h) compared to uninterrupted sitting3 hoursn = 21
Walking decreases systolic blood pressure in humans during interruptions of prolonged sitting (108 ± 10.6 vs. 114 ± 13.9 mmHg, p = 0.005, g = 0.48).
“MIPA significantly reduced systolic blood pressure (SBP) compared to control after 3 h (108 ± 10.6 vs. 114 ± 13.9 mmHg; p = 0.005; Δ≈−6 mmHg; g = 0.48)”
Human trialduring interruptions of prolonged sittingwalking5 min every 50 min at 6.0 km/h3 hn = 21
Walking decreases systolic blood pressure in humans (metabolic syndrome and MASLD) (-9.6%).
“along with significant reductions in systolic blood pressure (-9.6%) and blood glucose (-16.9%), as well as notable improvements in lipid profiles (p < 0.001).”
Human trialmetabolic syndrome and MASLDtreadmill walking program12 weeksn = 66
Walking showed no clear effect on depressive symptoms in humans.
“Furthermore, no statistically significant interaction effects between time and condition were found for any of the outcomes, indicating that the change over time did not differ between conditions.”
Walking decreases depressive symptoms in humans (MOD × 3 days/week compared to CON) (Cohen’s d = 1.57, p = 0.004).
“According to the post hoc analyses, HADS-depression and HADS-anxiety were lower in MOD × 3 days/week and VIG × 3 days/week groups after 12 weeks of walking training compared to CON (HADS-depression: MOD × 3 days/week–CON, Cohen’s d = 1.57, p = 0.004; VIG × 3 days/week–CON, Cohen’s d = −2.21, p = 0.0003) (HADS-anxiety: MOD × 3 days/week–CON, Cohen’s d = 1.02, p = 0.01; VIG × 3 days/week–CON, Cohen’s d = −1.31, p = 0.001”
Human trialMOD × 3 days/week compared to CON12 weeksn = 46
Walking improves VO2MAX in humans (-11.8% vs +16.1%).
“the CON group presented a decrease of 11.8%, whereas the WPG group presented a 16.1% increase, resulting in a significant difference between the groups (p < 0.001) after the 12-week period”
Walking improves VO2MAX in humans (type 2 diabetes).
“VO2max, HbA1c, and HOMA-IR in the 10/100MW and 10KS groups showed significant and comparable improvements postintervention compared to preintervention (p < 0.05).”
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·
Sleep quality
↑upin humans4
4 studies
Walking improves sleep quality in humans (menopausal women; walking program using WalkON).
“sleep quality scores in the intervention group decreased significantly following the walking intervention, indicating that sleep quality improved in the intervention group”
Human trialmenopausal women; walking program using WalkON12 weeksfemales
Walking improves sleep quality in humans (MOD × 3 days/week compared with CON) (Cohen’s d = 0.82, p = 0.02).
“The post hoc comparisons showed that both groups with three sessions weekly had improved self-perceived sleep quality compared with the CON group (MOD × 3 days/week–CON, Cohen’s d = 0.82, p = 0.02; VIG × 3 days/week–CON, Cohen’s d = −1.32, p = 0.001), whereas only the once-weekly vigorous-intensity walking showed improved self-perceived sleep quality (VIG × 1 day/week–CON, Cohen’s d = 1.52, p = 0.002”
Human trialMOD × 3 days/week compared with CON12 weeksn = 46
Walking improves sleep quality in humans (older adults with depressive symptoms and insomnia) (-31.4% to -38.3% of PSQI vs CON, p < 0.05).
“Self-perceived sleep quality was improved in MOD × 3/week (-31.4% of the Pittsburgh Sleep Quality Index [PSQI]), VIG × 1/week (-34.1% of PSQI), and VIG × 3/week (-38.3% of PSQI)”
Human trialolder adults with depressive symptoms and insomnia12 weeks
Walking improves 6-minute walk distance in humans.
“The walking exercise group also presented a longer distance when compared to the other groups; control (p = 0.038), supplement product (p = 0.048), and supplement product and walking exercise (p = 0.035).”
Walking improves 6-minute walk distance in humans.
“The walking exercise group also presented a longer distance when compared to the other groups; control (p = 0.038), supplement product (p = 0.048), and supplement product and walking exercise (p = 0.035).”
Walking improves cardiorespiratory fitness in humans (p < 0.05).
“The walking exercise interventions also significantly mitigated the anxiety severity (p < 0.005) and improved the cardiorespiratory fitness (p < 0.05) of the participants in the walking exercise groups.”
Walking improves cardiorespiratory fitness in humans (VIG groups compared with CON) (Cohen’s d = 0.45, p = 0.001).
“The post hoc analyses showed that all VIG groups, but not MOD groups, had improved cardiorespiratory fitness compared with CON (VIG × 1 day/week–CON, Cohen’s d = 0.75, p = 0.005; VIG × 3 days/week–CON, Cohen’s d = 0.45, p = 0.001).”
Human trialVIG groups compared with CON12 weeksn = 46
Walking improves quality of life in humans (older adults with mild to moderate cognitive impairment in assisted living).
“Significant effects favoring the intervention were shown for all outcomes.”
Human trialolder adults with mild to moderate cognitive impairment in assisted livingwatch-prompted light walking10 min three times a day10 weeksn = 25
“For LSE total scores, the aMD was − 2.156 points for walking vs. control (95% CI: -3.528, -0.784; p = 0.001; ηp2 = 0.304; Hedges’s g = -0.942), -4.095 points for DMT vs. control (95% CI: -5.468, -2.723; p < 0.001; ηp2 = 0.621; Hedges’s g = -0.884), and − 1.939 points for DMT vs. walking (95% CI: -3.312, -0.566; ηp2 = 0.402; Hedges’s g = 0.058; p = 0.003”
Walking decreases loneliness in humans (older people).
“both DMT and walking groups showed significant improvements in emotional loneliness, social loneliness, total ESNS, and LSE compared to the control group”
Walking was not clearly linked with bone mineral density in humans (femoral neck P = .092, calcaneus P = .367).
“However, there was no significant relationship between daily step recommendation adherence and BMD at the femoral neck (P = .092) or the heel (calcaneus P = .367).”
Walking is linked with higher bone mineral density in humans (walking 5 days or more per week for at least 30 min per day).
“The BMD and SMI in the group in which walking activity was performed 5 days or more per week for at least 30 min per day were significantly higher than those in the group in which walking activity was not performed.”
Humanswalking 5 days or more per week for at least 30 min per day
Walking is linked with a lower risk of mortality in humans (highest categories of physical activity levels vs lowest) (HR 0.83 (95% CI 0.80 to 0.85)).
“The pooled multivariable adjusted hazard ratios for all cause mortality in the highest categories of physical activity levels, compared with the lowest, were 0.83 (95% confidence interval 0.80 to 0.85) for walking”
Humanshighest categories of physical activity levels vs lowest
Journal of the American Medical Directors Association·
All 18Fewer
Dementia
↓downin humans4↔no changein humans1HR 0.59–0.72
4 studies
Walking is associated with dementia in patients with Parkinson's disease (HR 0.69, 95% CI 0.41-1.17).
“The MAE-weekly and MAE-daily groups were 0.69 (95% confidence interval (CI): 0.41-1.17) and 0.59 (95% CI: 0.41-0.84) times, respectively, less likely to develop dementia than the MAE-no group.”
Humansin patients with Parkinson's diseasefrequency: 1 or 2 per week (approx 1500-3000 steps or 15-30 min)n = 470
Walking is linked with a lower risk of dementia in patients with Parkinson's disease (HR 0.59, 95% CI 0.41-0.84).
“The MAE-weekly and MAE-daily groups were 0.69 (95% confidence interval (CI): 0.41-1.17) and 0.59 (95% CI: 0.41-0.84) times, respectively, less likely to develop dementia than the MAE-no group.”
Humansin patients with Parkinson's diseasefrequency: >=3 per week (approx 1500-3000 steps or 15-30 min)n = 470
International journal of environmental research and public health·
Walking is linked with a lower risk of dementia in humans (HR 0.72 (95% CI 0.53–0.97)).
“persons who remained in the highest category (≥1 h/day in both 1994 and 2006) had a significantly lower risk of incident dementia: the multivariate-adjusted HR (95% confidence intervals) was 0.72 (0.53 and 0.97).”
Humansremained in highest walking category (≥1 h/day in both 1994 and 2006) vs lowest (<0.5 h/day)5.7 years follow-upn = 6,909
“Walking decreases the risk or severity of various health outcomes such as cardiovascular and cerebrovascular diseases, type 2 diabetes mellitus, cognitive impairment and dementia”
Walking is associated with depression in humans (-72%, OR = 0.28, 95% CI 0.11-0.76, p = .012).
“the probability of depression was reduced by 72% when individuals walked a minimum of five miles per week compared with those who walked less than a block (OR = 0.28, 95% CI 0.11-0.76, p = .012).”
The journals of gerontology. Series A, Biological sciences and medical sciences·
Walking is associated with cognitive function in humans.
“Composite or total walking had a statistically significant association with global cognitive function and perceptual speed, after adjustments were made.”
Walking is linked with a lower risk of depressive symptoms in humans (without a history of depressive symptoms at baseline) (OR = 0.53, 95% CI = 0.30-0.93).
“Participants walking ≥150 min/week had lower odds (OR = 0.53, 95% CI = 0.30-0.93) of developing depressive symptoms over time than non-walkers.”
Humanswithout a history of depressive symptoms at baseline≥150 min/week9-year periodn = 836
Walking is linked with a lower risk of depressive symptoms in humans (without a history of depressive symptoms at baseline) (OR = 0.53, 95% CI = 0.30-0.93).
“those who walked ≥150 minutes/week had lower odds (OR = 0.53, 95% CI = 0.30-0.93) of developing depressive symptoms over time compared to non-walkers”
Humanswithout a history of depressive symptoms at baseline≥150 minutes/week9-yearn = 836
Walking is associated with physical function in humans (coefficient .002, 95% CI .001-.003, P<.0001).
“Change in PCS score was associated with kcals/week at 12 months in multivariable analysis controlling for enrollment kcals/week and PCS score (coefficient .002, 95% CI .001-.003, P<.0001).”
Walking is associated with body weight in humans (Chinese occupational population) (Weight β −1.03 (95% CI −1.51, −0.55) per 10,000-step rise in average daily steps).
“Each 10,000-step rise in average daily steps was significantly associated with lower BMI, weight, WC, HC and WHR”
Human trialChinese occupational populationEach 10,000-step rise in average daily steps60 daysn = 400
Walking is associated with body weight in humans (|dav | ≤ 0.06).
“Body weight, BMI, and body fat percentage decreased significantly, whereas no statistically significant changes were observed in absolute lean mass or handgrip strength; all body-composition effects were small (|dav | ≤ 0.06).”
Walking is associated with body weight in humans (cardiovascular disease and/or type 2 diabetes; uncontrolled before-and-after comparison) (Small effect; | d a v | ≤ 0.06).
“Body weight, BMI, and body fat percentage decreased significantly”
Human trialcardiovascular disease and/or type 2 diabetes; uncontrolled before-and-after comparisonsmartphone-supported3 monthswomen and mensn = 419
Walking is associated with osteoporosis in humans (isotemporal substitution of 30 min daytime napping) (OR 0.90, 95% CI 0.85–0.95).
“In women, reallocating 30 min of daytime napping to walking was also associated with lower odds of QUS-defined osteoporosis ( OR : 0.90, 95% CI : 0.85–0.95).”
Humansisotemporal substitution of 30 min daytime napping30 minfemales
Walking lowers the risk of chronic disease in humans (bout cadence).
“individuals who walked faster and more frequently had significantly lower disease risk than those with slower cadence, even when total steps were similar”
Walking is associated with stress in humans (dav = −0.20).
“Favorable changes were observed in vigor (dav = 0.34), well-being (dav = 0.17), and happiness (dav = 0.15), together with a reduction in stress (dav = −0.20); the reduction in anxiety did not remain statistically significant after BH-FDR correction.”
Walking is associated with well-being in humans (dav = 0.17).
“Favorable changes were observed in vigor (dav = 0.34), well-being (dav = 0.17), and happiness (dav = 0.15), together with a reduction in stress (dav = −0.20); the reduction in anxiety did not remain statistically significant after BH-FDR correction.”
Walking is associated with well-being in humans (cardiovascular disease and/or type 2 diabetes; uncontrolled before-and-after comparison) (d a v = 0.17).
“Favorable changes were observed in vigor ( d a v = 0.34), well-being ( d a v = 0.17)”
Human trialcardiovascular disease and/or type 2 diabetes; uncontrolled before-and-after comparisonsmartphone-supported3 monthswomen and mensn = 419
Walking is associated with daily step count in humans (cardiovascular disease and/or type 2 diabetes; uncontrolled before-and-after comparison) (Approximately +1,000 steps/day; d a v = 0.41).
“Daily step count increased by approximately 1,000 steps/day ( d a v = 0.41).”
Human trialcardiovascular disease and/or type 2 diabetes; uncontrolled before-and-after comparisonsmartphone-supported3 monthswomen and mensn = 419
Studies name Clinical Dementia Rating as acting on walking.
Clinical Dementia Rating
↔no changein humans1
1 study
Clinical Dementia Rating was not clearly linked with walking in humans (Comparison across Clinical Dementia Rating groups; simple tasks with high intensity).
“By contrast, for simple tasks with high intensity (e.g. walking), no CDR group differences were noted.”
HumansComparison across Clinical Dementia Rating groups; simple tasks with high intensityn = 590
Adults with dementia walked 17.2 fewer minutes and lay awake 46.5 more minutes per day than cognitively unimpaired peers, after adjustment.Adults with dementia walked 17.2 fewer minutes and lay awake 46.5 more minutes per day than cognitively unimpaired peers, after adjustment.
In the 12-week trial, estimated differences in score trends versus controls were 0.39 for thinking and minus 1.28 for loneliness, favoring walking.In the 12-week trial, estimated differences in score trends versus controls were 0.39 for thinking and minus 1.28 for loneliness, favoring walking.